Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis
Yang, C.W.; Vlassara, H.; Striker, G.E.; Striker, L.J.
Kidney International. Supplement 49: S55-S58
1995
ISSN/ISBN: 0098-6577 PMID: 7674596 Document Number: 442993
Administration of advanced glycosylation end products (AGEs), prepared on mouse albumin, to normal young adult mice, resulted in an increase in mean glomerular volume and up-regulation of laminin B1 and alpha-1 type IV collagen mRNAs measured by competitive PCR in single microdissected glomeruli. Both glomerular hypertrophy and overexpression of genes coding for extracellular matrix were abrogated when aminoguanidine, an inhibitor of AGE cross-linking, was added to the AGEs injections, suggesting that the glomerular response to AGEs was specific. The effects of AGEs administration in vivo are comparable to those occurring in the early stage of diabetic nephropathy, suggesting a participation of AGEs in these events.